ASCO submitted written testimony asking Congress to increase federal support for the National Institutes of Health (NIH) and the Beau Biden Cancer Moonshot Initiative in fiscal year 2018 (FY18).
ASCO in Action regularly provides the latest news and analysis related to cancer policy news; see the following online articles. These updates provide snapshots of ASCO’s ongoing advocacy efforts, as well as opportunities for ASCO members and guests to take action on critical issues affecting the cancer community.
To sign up for advocacy alerts, log in to ASCO.org with your ASCO member or guest account, and visit the subscription center available under your account profile.
ALEXANDRIA, Va. -- CancerLinQ LLC, a wholly-owned nonprofit subsidiary of the American Society of Clinical Oncology (ASCO), and the Oncology Nursing Society (ONS) announced today the formation of the CancerLinQ® Ambassadors Program. This new collaboration is a national practice engagement initiative that will provide on-the-ground support and guidance to CancerLinQ® participating practices on a regional basis.
ASCO recently joined more than 100 medical specialty groups and state medical societies in signing an American Medical Association-led letter urging the Centers for Medicare & Medicaid Services (CMS) and Office of the National Coordinator for Health Information (ONC) to delay requiring 2015 Edition Certified Electronic Health Record Technology (CEHRT) until such technology is widely available—and no sooner than January 2019.
The American Society of Clinical Oncology (ASCO) will release The State of Cancer Care in America: 2017 at a briefing on Capitol Hill on March 22. The report examines the current landscape of the cancer care delivery system in the United States, and outlines key opportunities and challenges facing cancer care providers and patients today.
On March 06, 2017, the United States House of Representatives released the American Healthcare Act, a bill to repeal and partly replace the Affordable Care Act (ACA).
ASCO has submitted comments in response to the Affordable Care Act Market Stabilization proposed rule, published in the Federal Register on Feb. 17. The society has serious concerns that the proposal could reduce access to cancer care in significant ways.
ASCO is tracking legislation that would increase the legal age for the purchase of tobacco products to 21, known as “Tobacco 21,” in multiple states. ASCO worked closely with the Florida Society of Clinical Oncology to submit a joint letter of support on Florida bill 1093. ASCO also sent a support letter for West Virginia bill House bill 2331 and Senate bill 37 and Texas House bill 628 and 1908 and Senate bill 183 and 910.
On March 14, the Spring Round for ASCO’s Quality Oncology Practice Initiative (QOPI®) will open for reporting. Practices are encouraged to register now in preparation for the opening date.
On March 1, ASCO joined many national, state, and local organizations led by NDD United in sending a letter to Congress urging legislators to avoid making further reductions to nondefense discretionary or “NDD” government programs. NDD United formed in 2012 in response to the Budget Control Act of 2011, which established automatic across-the-board cuts to NDD programs. These NDD programs include medical research, public health, and other key programs critical to patients with cancer.
A new editorial in the Journal of Oncology Practice (JOP) from Arif Kamal, MD, MBA, MHS, Chair of ASCO’s Quality of Care Committee, discusses the importance of oncologists using available data to explore what patients and caregivers value most in cancer care delivery.
ASCO is partnering with four other healthcare provider organizations to conduct a survey that will examine the specific roles and responsibilities of advanced practice providers within the cancer care delivery team.
On February 23, 2017, ASCO launched its newest online-only journal, JCO Clinical Cancer Informatics (JCO CCI).
CancerLinQ LLC and the American Society for Radiation Oncology (ASTRO) are partnering to bring radiation oncology expertise to CancerLinQ® and improve the care of cancer patients nationwide. ASTRO will provide guidance for the development of the CancerLinQ® platform to ensure that the system captures more relevant patient data to drive actionable decision-making in cancer care, as well as to advance public policy and population health issues. ASTRO also will use insights from CancerLinQ Discovery™ to improve the care of patients receiving radiation therapy.
On February 22, 2017, the U.S. Food and Drug Administration approved lenalidomide (Revlimid®, Celgene Corp.) as maintenance therapy for patients with multiple myeloma following autologous stem cell transplant.
A variety of courses and resources are available for physicians to help guide patients with a cancer diagnosis through fertility preservation issues, a topic not often addressed soon enough with female and male patients between the ages of 15 and 39.